A COMPARATIVE CLINICAL TRIAL OF INTRAVESICAL BCG AND ARDIAMYCIN TREATMENT IN SUPERFICIAL BLADDER CANCER : A South West Oncology Group Study

  • Lamm Donald L.
    Department of Urology, West Virginia University School of Medicine
  • Mori Katsushi
    Division of Urology, The University of Texas Health Science Center at San Antonio
  • Crawford E.David
    Division of Urology, Mississippi University School of Medicine

Bibliographic Information

Other Title
  • 表在性膀胱腫瘍に対するBCG療法とアドリアマイシン膀胱内注入の臨床比較研究 : 米国南西部泌尿器科研究班の経験

Search this article

Description

In one hundred and sixty-two patients with superficial bladder cancer, confirmed by biopsy, the effects of intravesical BCG and Adriamycin were compared. The patients were followed up for 2 to 25 months (average, 15.7 months) by cystoscopy at 3 month intervals, urinary cytology and bladder cold cup biopsy. Of 104 patients with no evidence of carcinoma in situ (CIS), 12 of 52 patients (23 percent) who received intravesical BCG immunotherapy developed tumor recurrence, compared with 34 recurrences (65 percent) in 54 patients who received Adriamycin chemotherapy (p<0.001 X^2). Of 58 randomized patients who documented CIS, the complete response was noted in 22 of 30 patients (73 percent) who received BCG administration, compared with a complete response rate of only 29 percent in 28 patients with intravesical Adrianycin treatment (p<0.001, X^2). There was no significant correlation between the efficacy of either kind of treatment and chemotherapy prior to this study, although it was likely to have resulted in unfavorable response to intravesical Adriamycin. No serious complications were observed in both treatments except in patients with bladder irritability. These data suggest that BCG immunotherapy is superior to Adriamycin chemotherapy in the prevention of recurrent superficial transitional cell carcinoma and in the treatment of CIS of the urinary bladder.

Journal

Details 詳細情報について

Report a problem

Back to top